Comparative Pharmacology
Head-to-head clinical analysis: AZACTAM IN PLASTIC CONTAINER versus CAYSTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACTAM IN PLASTIC CONTAINER versus CAYSTON.
AZACTAM IN PLASTIC CONTAINER vs CAYSTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aztreonam binds to penicillin-binding proteins (PBPs) of susceptible bacteria, inhibiting bacterial cell wall synthesis. It is a monobactam with activity against aerobic gram-negative bacteria.
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is active against Gram-negative aerobic bacteria including Pseudomonas aeruginosa.
1-2 g IV/IM every 6-8 hours; maximum 8 g/day.
75 mg (one vial) inhaled via nebulizer three times daily, each dose approximately 4 hours apart.
None Documented
None Documented
1.7-2.1 hours (normal renal function); prolonged to 4.2-6.0 hours in ESRD (CrCl <10 mL/min).
Approximately 2.0–2.5 hours in patients with normal renal function. In patients with moderate renal impairment (CrCl 30–49 mL/min), half-life may be prolonged to ~4.5 hours.
Primarily renal (75-85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Primarily renal; >99% of the absorbed dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Category C
Category C
Monobactam Antibiotic
Monobactam Antibiotic